Home   /  Find a Trial  /  See All Trials HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

see All Trials

Sort by zip code:  




No Travel Required

Reproductive Health Survivorship Care Plan for Young Survivors

Intervening on Reproductive Health in Young Breast Cancer Survivors (NCT02667626)


Young breast cancer survivors frequently have concerns about fertility, birth control, and sexual function. Researchers have developed a survivorship care plan for young survivors that addresses these reproductive health issues. This study is comparing the effectiveness of two different survivorship care plans for young survivors. As part of the study, participants will discuss reproductive health issues with the healthcare provider of their choice. To be eligible, a woman must have been diagnosed with breast cancer within the past five years and must have been age 45 or younger at the time of her diagnosis.
This is a Phase III trial

Online-Based Decision Support for Metastatic Breast Cancer Patients

Four Conversations Randomized Controlled Trial (NCT02944344)


To take part in this study, you must have metastatic (stage IV) breast cancer. You must also have internet access through a computer, laptop, tablet or other mobile device. This study is looking at whether an online-based decision support program improves quality of care for metastatic breast cancer patients. The Four Conversations is an online-based decision support program designed to help patients with decision-making and care planning. It encourages patients to have four conversations: an informative conversation with healthcare professionals, a supportive conversation with family and friends, an inspirational conversation with or about spirituality, and an honest conversation with yourself.

BRCA Gene Mutations in Latinas with Breast Cancer

BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects (NCT01251900)


Some women who have triple negative (ER, PR, and HER2-negative) breast cancer also have a BRCA1 or BRCA2 genetic mutation. The number of Latinas with triple negative breast cancer who also have a BRCA1/2 mutation is not known. Learning more about BRCA1/2 mutation rates among Latinas will help researchers provide better treatment to this group of women. The purpose of this trial is to study DNA samples taken from saliva and the medical histories of Latinas who have been diagnosed with breast cancer. Participants can reside anywhere in the U.S.

Evaluating How Breast Cancer Affects Different Ethnic Groups

Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life (NCT01134172)


Little is known about how breast cancer treatments affect the employment, financial situation, and quality of life of ethnic minority women over a short- or long-term basis. The purpose of this study is to evaluate how breast cancer affects the lives of women from different ethnic groups. To be eligible, women must be receiving treatment for stage I, II or III breast cancer and have been employed prior to their diagnosis. Participants will be asked to find a peer who speaks the same language, is the same age and ethnicity, and will agree to take part in the study.

A Pregnancy Registry for Women on HER2-Targeted Therapies

An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta In Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior To Conception (NCT00833963)


Trastuzumab (Herceptin®), pertuzumab (Perjeta®) and ado-trastuzumab emtansine (Kadcyla®) are used to treat HER2-positive tumors. These drugs are not approved for use during pregnancy and carry labels that advise women to avoid becoming pregnant or breastfeeding. The MotHER Pregnancy Registry is a U.S.-based, prospective, observational study in women with breast cancer who received at least one dose of these drugs during pregnancy or within 6 months of conception. The primary objective of this Pregnancy Registry is to monitor women who were pregnant when receiving any of these medications to determine the frequency of adverse pregnancy complications or major birth defects.

WISDOM Study: Women Informed to Screen Depending on Measures of Risk

Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (NCT02620852)


To take part in this study, you must be between the ages of 40 and 70 and not have previously been diagnosed with breast cancer or ductal carcinoma in situ (DCIS). You must also be able to receive breast screening at an Athena site: University of California (San Francisco, San Diego, Davis, Los Angeles, and Irvine), or Sanford Health in South Dakota. This study is comparing risk-based screening to annual screening for measuring breast cancer risk and detecting breast cancer. It will help researchers learn if risk-based screening, which helps women learn more about their personal breast cancer risk, is less stressful and as successful at detecting breast cancer. The personalized risk-based screening will take multiple risk factors into consideration, including genetic markers, to determine how often you should have a mammogram.

The Health of Women Study: Learning About the Causes of and Ways to Prevent Breast Cancer

The Health of Women (HOW) Study (NCT02334085)


The Health of Women (HOW) study is an international online study for women and men with or without a history of breast cancer. Participants in this study complete questionnaires about their health, job, diet and family history, among other topics. The researchers will use the information collected from these questionnaires to gain insight into what causes breast cancer and how to prevent it. This study is open to all women and men of every age, ethnicity, sexual orientation and occupation.

Collecting Information About Metastatic Breast Cancer To Further Research

The Metastatic Breast Cancer Project (MAN002)


To take part in this study you must be a woman or man living with metastatic breast cancer. The goal of the Metastatic Breast Cancer Project is to accelerate research in treating, curing and preventing metastatic breast cancer. If you take part in the project, you will fill out questionnaires, provide a saliva sample, and share a piece of your stored tumor tissue and copies of your medical records with the researchers. The researchers believe analyzing this data will help them learn more about metastatic breast cancer and make more research advances. The Project was created by a coalition of researchers and breast cancer advocacy organizations.

A Study of the Inherited KRAS-Variant Mutation and Breast Cancer Risk

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment (NCT02253251)


Researchers have identified an inherited genetic mutation—a KRAS-variant—that may increase a person's risk of developing breast or other types of cancer. This study will follow participants for 10 years in order to analyze the association between the KRAS-variant mutation and cancer risk. The researchers will also look at the effect that different lifestyle factors have on cancer risk. All participants will have a saliva sample tested for the KRAS-variant. To be eligible, participants must have a personal or family history of breast cancer.

Study of Relationship Between Oral/Gut Microbiomes and Breast Cancer

Role of the Oral and Gut Microbiomes in Breast Cancer (MAN001)


Bacteria found in our mouth and our guts may provide information about our overall health. This study is investigating whether bacteria in the mouth or gut have any relation to breast cancer. For the study, researchers will compare bacterial DNA from cheek and stool samples provided by women with breast cancer and healthy women. This study is open to women with DCIS and invasive breast cancer who will be starting treatment. It is also open to healthy women. Women who have been treated for a prior cancer or DCIS are not eligible. For breast cancer patients, the bacteria samples can be provided after surgery. However, they must be provided before starting chemotherapy, hormone therapy, targeted therapy or radiation.

<<   1   >>   Show All Results